Michel Ducreux
0000-0001-8649-7449
Publication & Citation Trends
Publications
0 total
Landmark analysis of overall survival (OS) by objective response in patients (pts) with previously treated, advanced HER2-positive biliary tract cancer (BTC): Post hoc analysis of the HERIZON-BTC-01 trial.
Cited by 0
Semantic Scholar
A phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 (GSK’227), alone and in combination in patients with previously treated advanced unresectable or metastatic gastrointestinal solid tumors.
Cited by 0
Semantic Scholar
A phase 2/3 randomized study of BMS-986504 with nab-paclitaxel (nab-P) and gemcitabine (GEM) in first-line (1L) metastatic pancreatic ductal adenocarcinoma (PDAC) with homozygous MTAP deletion ( MTAP -del): MountainTAP-30.
Cited by 0
Semantic Scholar
Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150
Cited by 10
Semantic Scholar
Two-stage Hepatectomy Versus Liver Transplantation for Patients with Marginally Resectable Extensive Bilobar Colorectal Liver Metastases.
Cited by 2
Semantic Scholar
Abstract CT169: Phase Ib/II open-label, randomized study of atezolizumab + regorafenib + AB928 or atezolizumab + regorafenib vs regorafenib for patients with microsatellite-stable, refractory metastatic colorectal cancer in MORPHEUS-CRC
Cited by 0
Semantic Scholar
Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150 OA
Cited by 34
Semantic Scholar
Safety and feasibility of chemotherapy followed by liver transplantation for patients with definitely unresectable colorectal liver metastases: insights from the TransMet randomised clinical trial
Cited by 23
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(381)
Hepatocellular Carcinoma Treatment and Prognosis
(245)
Pancreatic and Hepatic Oncology Research
(184)
Gastric Cancer Management and Outcomes
(148)
Neuroendocrine Tumor Research Advances
(140)
Affiliations
Université Claude Bernard Lyon 1
Université Paris-Sud
AstraZeneca (United Kingdom)
Novartis (Switzerland)
Radboud University Nijmegen